A recent study has demonstrated that high-sensitivity C-reactive protein, a representative inflammation marker, is a stronger predictor for risk of future cardiovascular events and death in patients taking statins than cholesterol assessed by LDL cholesterol, which is already well known to have a strong correlation with cardiovascular disease [44]. This evidence concerns the gene CRP and cardiovascular disorder.